Pfizer Q2 Results: Profit tumbles 77% to $2.3 billion; co trims 2023 revenue outlook
These include US approval for a drug combination for prostate cancer and a needed recommendation on the Abrysvo vaccine from the US Centers for Disease Control and Prevention
